TP53 and ovarian serous adenocarcinoma: This drug has been shown to have good efficacy against small cell lung carcinoma [164], breast cancer [165], thyroid cancer [166], acute promyelocytic leukemia [167], high-grade serous ovarian cancer [168], acute myeloid leukemia cells [169], epithelial ovarian cancer cells [170], soft-tissue sarcomas cell independent of p53 [171], and multiple myeloma [136,144,172,173].